126 related articles for article (PubMed ID: 38653530)
21. Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune checkpoint inhibitors for cancer.
McCarter KR; Arabelovic S; Wang X; Wolfgang T; Yoshida K; Qian G; Kowalski EN; Vanni KMM; LeBoeuf NR; Buchbinder EI; Gedmintas L; MacFarlane LA; Rao DA; Shadick NA; Gravallese EM; Sparks JA
Semin Arthritis Rheum; 2024 Feb; 64():152335. PubMed ID: 38100899
[TBL] [Abstract][Full Text] [Related]
22. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
Taylor PC; Keystone EC; van der Heijde D; Weinblatt ME; Del Carmen Morales L; Reyes Gonzaga J; Yakushin S; Ishii T; Emoto K; Beattie S; Arora V; Gaich C; Rooney T; Schlichting D; Macias WL; de Bono S; Tanaka Y
N Engl J Med; 2017 Feb; 376(7):652-662. PubMed ID: 28199814
[TBL] [Abstract][Full Text] [Related]
23. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
24. Performance of the Rheumatoid Arthritis Impact of Disease (RAID) score in relation to flares in disease activity.
Holten K; Paulshus Sundlisæter N; Sexton J; Nordberg LB; Uhlig T; Kvien TK; Solomon DH; Haavardsholm EA; Lillegraven S; Aga AB;
RMD Open; 2024 Jan; 10(1):. PubMed ID: 38216290
[TBL] [Abstract][Full Text] [Related]
25. Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set.
Bykerk VP; Bingham CO; Choy EH; Lin D; Alten R; Christensen R; Furst DE; Hewlett S; Leong A; March L; Woodworth T; Boire G; Haraoui B; Hitchon C; Jamal S; Keystone EC; Pope J; Tin D; Thorne JC; Bartlett SJ
RMD Open; 2016; 2(1):e000225. PubMed ID: 27252895
[TBL] [Abstract][Full Text] [Related]
26. Proteasome-associated autoinflammatory syndromes: advances in pathogeneses, clinical presentations, diagnosis, and management.
McDermott A; Jacks J; Kessler M; Emanuel PD; Gao L
Int J Dermatol; 2015 Feb; 54(2):121-9. PubMed ID: 25521013
[TBL] [Abstract][Full Text] [Related]
27. Disease activity flares and pain flares in an early rheumatoid arthritis inception cohort; characteristics, antecedents and sequelae.
McWilliams DF; Rahman S; James RJE; Ferguson E; Kiely PDW; Young A; Walsh DA
BMC Rheumatol; 2019; 3():49. PubMed ID: 31832600
[TBL] [Abstract][Full Text] [Related]
28. How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index.
Thanou A; Chakravarty E; James JA; Merrill JT
Rheumatology (Oxford); 2014 Dec; 53(12):2175-81. PubMed ID: 24729400
[TBL] [Abstract][Full Text] [Related]
29. Successful treatment of chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome with tofacitinib.
Patel PN; Hunt R; Pettigrew ZJ; Shirley JB; Vogel TP; de Guzman MM
Pediatr Dermatol; 2021 Mar; 38(2):528-529. PubMed ID: 33512037
[TBL] [Abstract][Full Text] [Related]
30. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
Eichenfield LF; Gower RG; Xu J; Alam MS; Su JC; Myers DE; Sanders P; Vlahos B; Zang C; Lan J; Werth J
Am J Clin Dermatol; 2023 Jul; 24(4):623-635. PubMed ID: 37184828
[TBL] [Abstract][Full Text] [Related]
31. Prevalence and factors associated with flares following COVID-19 mRNA vaccination in patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: a national cohort study.
Fong W; Woon TH; Chew LC; Low A; Law A; Poh YJ; Yeo SI; Leung YY; Ma M; Santosa A; Kong KO; Xu C; Teng GG; Mak A; Tay SH; Chuah TY; Roslan NE; Angkodjojo S; Phang KF; Sriranganathan M; Tan TC; Cheung P; Lahiri M
Adv Rheumatol; 2023 Aug; 63(1):38. PubMed ID: 37528453
[TBL] [Abstract][Full Text] [Related]
32. Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis.
Lopez-Romero P; de la Torre I; Haladyj E; Aletaha D; Smolen JS
Ann Rheum Dis; 2022 May; 81(5):622-631. PubMed ID: 35193872
[TBL] [Abstract][Full Text] [Related]
33. Patient-defined flares and disease activity worsening in 222 patients with psoriatic arthritis from 14 countries.
Sousa M; Lubrano E; Smolen JS; Gorlier C; de Wit M; Coates LC; Kalyoncu U; Ruyssen-Witrand A; Leung YY; Scrivo R; Cañete JD; Palominos P; Meisalu S; Balanescu A; Kiltz U; Aydin SZ; Gaydukova I; Dernis E; Fautrel B; Orbai AM; Gossec L
Joint Bone Spine; 2023 May; 90(3):105511. PubMed ID: 36529417
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis.
Tanaka Y; Fautrel B; Keystone EC; Ortmann RA; Xie L; Zhu B; Issa M; Patel H; Gaich CL; de Bono S; Rooney TP; Taylor PC
Ann Rheum Dis; 2019 Jul; 78(7):890-898. PubMed ID: 31040122
[TBL] [Abstract][Full Text] [Related]
35. Treatment of severe alopecia areata with baricitinib.
Olamiju B; Friedmann A; King B
JAAD Case Rep; 2019 Oct; 5(10):892-894. PubMed ID: 31681829
[No Abstract] [Full Text] [Related]
36. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).
Morand EF; Vital EM; Petri M; van Vollenhoven R; Wallace DJ; Mosca M; Furie RA; Silk ME; Dickson CL; Meszaros G; Jia B; Crowe B; de la Torre I; Dörner T
Lancet; 2023 Mar; 401(10381):1001-1010. PubMed ID: 36848918
[TBL] [Abstract][Full Text] [Related]
37. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis.
Winthrop KL; Harigai M; Genovese MC; Lindsey S; Takeuchi T; Fleischmann R; Bradley JD; Byers NL; Hyslop DL; Issa M; Nishikawa A; Rooney TP; Witt S; Dickson CL; Smolen JS; Dougados M
Ann Rheum Dis; 2020 Oct; 79(10):1290-1297. PubMed ID: 32788396
[TBL] [Abstract][Full Text] [Related]
38. Serial magnetic resonance imaging and ultrasound examinations demonstrate differential inflammatory lesion patterns in soft tissue and bone upon patient-reported flares in rheumatoid arthritis.
Kuettel D; Glinatsi D; Østergaard M; Terslev L; Primdahl J; Möller S; Pedersen A; Petersen R; Weber U; Hørslev-Petersen K
Arthritis Res Ther; 2020 Feb; 22(1):19. PubMed ID: 32014018
[TBL] [Abstract][Full Text] [Related]
39. Validation and predictive capacity of a Dutch version of the FLARE-RA questionnaire within the context of a TNFi-tapering trial.
Doumen M; Bertrand D; Pazmino S; De Cock D; Stouten V; Joly J; de Wergifosse I; Moeyersoons A; Westhovens R; Verschueren P
Clin Rheumatol; 2023 Jan; 42(1):39-45. PubMed ID: 35943667
[TBL] [Abstract][Full Text] [Related]
40. Stopping bDMARDs at the beginning of pregnancy is associated with disease flares and preterm delivery in women with rheumatoid arthritis.
Gerardi MC; Crisafulli F; García-Fernandez A; Lini D; Bazzani C; Cavazzana I; Filippini M; Fredi M; Gorla R; Lazzaroni MG; Nalli C; Taglietti M; Lojacono A; Ramazzotto F; Zanardini C; Zatti S; Franceschini F; Tincani A; Andreoli L
Front Pharmacol; 2022; 13():887462. PubMed ID: 35991899
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
